Category: Clinical Trials

Weight loss: GI Dynamics' U.S. clinical trial taxes its coffers

May 20, 2013 by Arezu Sarvestani

Investors Down Under shied away from weight-loss devices maker GI Dynamics (ASX:GID) today after president & CEO Stuart Randle told shareholders that the company may need to raise new funds in order to support its clinical trials.

Direct Flow Medical wins FDA approval for U.S. trial of new heart valve

May 17, 2013 by Ingrid Mezo

The FDA granted Direct Flow Medical an investigational device exemption for its transcatheter aortic valve implant, with the medical device company announcing enrollment in its Salus feasibility trial.

Pluristem launches Phase I clinical trial to treat tendonitis with stem cells

May 17, 2013 by Sony Salzman

Pluristem (NSDQ:PSTI) announced a new Phase I clinical trial to treat chronic tendonitis with the company's PLX-PAD stem cell therapy.

Cell therapy has traditionally been used in cancer and cardiac treatments, but Pluristem is now applying the technology to sports-related injuries, where it has seen an increased interest among athletes and orthopedic surgeons.

Boston Scientific hits new 52-week high on WallFlex stent trial launch

May 15, 2013 by Brad Perriello

Boston Scientific (NYSE:BSX) shares hit a new 52-week high today after the medical device company announced the launch of a clinical trial of its WallFlex biliary stent.

Valve-in-valve implantation for failed heart valves shows good short-term results

May 15, 2013 by Ingrid Mezo

The short-term results of minimally invasive transcatheter valve-in-valve implantation to treat failed biological heart valve protheses are "excellent," but patients must be closely monitored due to some notable cases of suboptimal systolic-valve performance, according to early data from a multi-center trial.

St. Jude Medical kicks off renal denervation device study

May 14, 2013 by Ingrid Mezo

The 1st patient enrolled today in a St. Jude Medical (NYSE:STJ)-sponsored trial to evaluate the safety and performance of a new renal denervation system in patients with drug-resistant, uncontrolled hypertension, the company said.

Elixir goes head-to-head against Medtronic with its DESyne Nx DES study

May 13, 2013 by Sony Salzman

With a green-light from the FDA, Elixir Medical Corporation will move forward with its Excella III pivotal trial to review its DESyne Nx Novolimus-eluting coronary stent system. Elixir plans to enroll patients at 50 clinical locations and will use the trial results to support its upcoming premarket approval application.